BACK TO CONTENTS
FOCUS 22
by PROF HILARY THOMAS, DR LIZZIE TUCKEY
BUSTING THE
NICHE: THE FUTURE OF GENOMICS
The sequencing of patients' genes has opened the way for exciting new approaches to therapy. The challenge for the pharmaceutical and life sciences sectors is to adapt R&D, production and sales and marketing to become swift, agile developers of more specialised drugs and smaller target audiences.
© 2014 KPMG LLP, a UK limited liability partnership, and a member fi rm of the KPMG network of independent member fi rms affi liated with KPMG International Cooperative, a Swiss entity. All rights reserved. B
y the time the fi rst human genome was sequenced in 2004, the total cost of reaching this goal had soared to £1.6 bn over 14 years1 Fast-forward a decade, and
.
Illumina’s HiSeq X Ten sequencing platform can carry out the task in less than 24 hours for just £600.
These achievements have generated
considerable excitement over the potential for genomics to herald a new era of personalised medicine, where customised information can be used for prevention, diagnosis and
treatment. Consequently, genomics has become a high priority for biomedical research, with the pharmaceutical and life sciences sectors desperate for ‘nichebuster’ breakthroughs to compensate for the decline in blockbuster drugs.
Frustratingly, though, genomics has so far failed to yield much in the way of specifi c treatments, while health systems are still working out how best to share and use the vast amount of data accruing from sequencing and other research.
1
wired.co.uk/news/archive/2014-01/15/1000-dollar-genome
GENOMICS
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41